港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

映恩生物-B

204.600

-21.000-9.31%

成交量：171.06萬

成交額：3.65億

市值：185.11億

市盈率：-4.44

高：235.000

開：235.000

低：202.000

收：225.600

52周最高：563.500

52周最低：188.100

股本：9,047.56萬

香港流通股本：9,047.56萬

量比：1.87

換手率：1.89%

股息：- -

股息率：- -

每股收益(LYR):-46.101

淨資產收益率：-1282.14%

總資產收益率：-9.61%

市淨率：6.59

市盈率(LYR):-4.44

市銷率: 8.63

資料載入中...

總覽公司新聞資訊公告

異動解讀｜映恩生物-B盤中下跌5.59%，報213.0港元

映恩生物-B回購4.2萬股股份併發行2萬股新股

異動解讀｜映恩生物-B盤中上漲5.16%，ASCO年會開幕疊加核心管線臨床推進提振板塊情緒

映恩生物-B5月28日回購4.78萬股股份，總額約1,017.57萬港元

映恩生物-B(09606)5月28日耗資1017.57萬港元回購4.78萬股

映恩生物－Ｂ(09606)出現大手賣出6.29萬股，成交價$209.2，涉資1.316千萬

阿斯达克财经

異動解讀｜映恩生物-B盤中下跌5.38%，報211.0港元

港股異動 | 映恩生物-B(09606)升逾5% 與BioNTech合作開發B7-H3 ADC全球Ⅲ期臨床完成首例患者給藥

異動解讀｜映恩生物-B盤中上漲5.36%，回購計劃持續落地疊加機構增持提振市場信心

映恩生物－Ｂ(09606)出現大手買入3.5萬股，成交價$214.0，涉資749萬

阿斯达克财经

映恩生物-B回購3萬股股份，耗資約651.44萬港元

映恩生物-B(09606)5月26日斥資651.44萬港元回購3萬股

LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股每股作價226.0879港元

映恩生物-B早盤漲近5% 擬回購最多4000萬美元股份

異動解讀｜映恩生物-B盤中上漲5.66%，行使DB-1311美國市場選擇權後連續下挫迎來反彈

映恩生物-B(09606)擬回購最多4000萬美元股份創始人朱忠遠擬增持不超過500萬美元股份

映恩生物-B(09606)：通知行使DB-1311/BNT324成本及利潤╱虧損分擔選擇權

映恩生物-B4月股份變動月報披露，股本小幅增加

映恩生物-B（09606）2025年ADC佈局穩步拓展，收入18.52億元、淨虧損擴大至25.95億元

《大行》中金列出內地主動偏股型基金於港股首季重倉股情況(表)

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":204.6,"timestamp":1780301307007,"preClose":225.6,"halted":0,"volume":1710564,"delay":0,"changeRate":-0.09308510638297872,"floatShares":90475600,"shares":90475600,"eps":-46.10453661901179,"marketStatus":"未開盤","change":-21,"latestTime":"06-01 16:08:27","open":235,"high":235,"low":202,"amount":364953557,"amplitude":0.146277,"askPrice":204.8,"askSize":100,"bidPrice":204.6,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":-36.92069826937547,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":225.6,"openAndCloseTimeList":[[1780277400000,1780286400000],[1780290000000,1780300800000]],"volumeRatio":1.872144,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90475600,"roa":"-9.61%","roe":"-1282.14%","lyrEps":-46.101056,"volumeRatio":1.872144,"shares":90475600,"dividePrice":0,"high":235,"amplitude":0.146277,"preClose":225.6,"low":202,"week52Low":188.1,"pbRate":"6.59","psRate":"8.63","week52High":563.5,"institutionHeld":0,"latestPrice":204.6,"committee":0.913043,"eps":-46.10105576674374,"divideRate":0,"volume":1710564,"delay":0,"ttmEps":-36.91791078888584,"open":235,"prevYearClose":298.2,"prevWeekClose":225.6,"prevMonthClose":225.6,"prevQuarterClose":295,"fiveDayClose":222.8,"twentyDayClose":276,"sixtyDayClose":299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1761408000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-05-29","current":-5.541607,"percent":0.974545,"low":-29.984477,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"high":-6.033707,"avg":-12.91758,"sd":6.15558,"marketCap":20400514838},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838}],"updateTime":1780333029567},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187714473","title":"異動解讀｜映恩生物-B盤中下跌5.59%，報213.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187714473","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187714473?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 11:07","pubTimestamp":1780283268,"startTime":"0","endTime":"0","summary":"6月1日，映恩生物-B盘中下跌5.59%，报213.0港元/股，成交额1.52亿港元。映恩生物-B所在的生物科技行业中，板块表现分化，个股中，康方生物涨2.37%，三生制药涨1.14%，信达生物跌2.64%，百济神州跌2.32%，科伦博泰生物跌3.25%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185215681","title":"映恩生物-B回購4.2萬股股份併發行2萬股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185215681","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185215681?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 18:46","pubTimestamp":1780051570,"startTime":"0","endTime":"0","summary":"2026年5月29日，映恩生物-B发布翌日披露报表，宣布于当日回购4.2万股普通股，占当日回购前已发行股本约0.0464%。回购价格介于每股210.40港元至228.40港元，总耗资约9,374,180港元，并将回购股份列作库藏股。回购及新股发行完成后，公司已发行股本由原先的90,497,614股调整为90,475,614股，库藏股数量增至119,800股。据披露，映恩生物-B于2025年6月20日获批准的购回授权可回购股份总数为8,803,626股，截至目前累计已回购119,800股，占授权通过当日已发行股份总数约0.14%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B回购4.2万股股份并发行2万股新股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112306759","title":"異動解讀｜映恩生物-B盤中上漲5.16%，ASCO年會開幕疊加核心管線臨床推進提振板塊情緒","url":"https://stock-news.laohu8.com/highlight/detail?id=1112306759","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112306759?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 11:32","pubTimestamp":1780025535,"startTime":"0","endTime":"0","summary":"5月29日，映恩生物-B盘中上涨5.16%，报220.0港元，成交额1.08亿港元。消息面上，ASCO年会于5月29日正式开幕，ADC赛道为本届重点关注方向之一，生物科技板块整体走强，信达生物涨10.22%、康方生物涨6.07%。此外，公司持续落地回购计划，5月26日及28日分别回购3万股及4.78万股，知名机构LAV Asset Management亦于5月20日增持10.5万股，多重利好共振提振市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100033219","title":"映恩生物-B5月28日回購4.78萬股股份，總額約1,017.57萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100033219","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100033219?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 18:50","pubTimestamp":1779965412,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年5月28日发布公告，当日公司在香港联交所回购47,800股普通股，约占回购前已发行股本的0.0528%。回购价格介乎每股港币208.4元至217.6元，合计动用资金约港币1,017.57万元，上述回购股份将以库存股份方式持有。此外，公司于2026年5月27日和5月28日分别因非发行人的董事行使购股权，发行12,600股及8,400股普通股，发行价分别为每股港币215.9159元及港币216.4881元，合计发行股数为21,000股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B5月28日回购4.78万股股份，总额约1,017.57万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2638662056","title":"映恩生物-B(09606)5月28日耗資1017.57萬港元回購4.78萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638662056","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638662056?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 18:45","pubTimestamp":1779965129,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)公布，2026年5月28日耗资1017.57万港元回购4.78万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","09606","HK0000252152.HKD","BK1161","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665720","title":"映恩生物－Ｂ(09606)出現大手賣出6.29萬股，成交價$209.2，涉資1.316千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665720","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638665720?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 14:04","pubTimestamp":1779948240,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在下午02:04出现大手卖出，成交量为6.29万，成交价为港币$209.2，涉资1.316千万。至目前为止，股价跌5.83%，今日最高价为$226.4，而最低价为$209.0，总成交量为64.699万股，总成交金额港币$1.378亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605289053/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605289053/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2543165471.USD","HK0000252160.HKD","BK1161","HK0000500386.USD","09606","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111504352","title":"異動解讀｜映恩生物-B盤中下跌5.38%，報211.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111504352","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111504352?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 13:02","pubTimestamp":1779944522,"startTime":"0","endTime":"0","summary":"5月28日，映恩生物-B盘中下跌5.38%，报211.0港元/股，成交额6681.77万港元。映恩生物-B所在的生物科技行业中，板块整体承压，个股中，信达生物跌2.15%，康方生物跌2.78%，派格生物医药-B跌2.72%，三生制药跌5.95%，百济神州跌2.21%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股異動 | 映恩生物-B(09606)升逾5% 與BioNTech合作開發B7-H3 ADC全球Ⅲ期臨床完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638457426?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK4588","BK1161","LU2543165471.USD","BK4585","HK0000252152.HKD","ADC","BK4231","09606","HK0000500386.USD","BK4080","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110943067","title":"異動解讀｜映恩生物-B盤中上漲5.36%，回購計劃持續落地疊加機構增持提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1110943067","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110943067?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 13:43","pubTimestamp":1779860595,"startTime":"0","endTime":"0","summary":"5月27日，映恩生物-B盘中上涨5.36%，报228.2港元，成交额1.12亿港元。消息面上，公司于5月26日在公开市场回购3万股股份，耗资约651.44万港元，回购价格介于每股216.20至218.40港元，回购股份以库藏股形式持有。此次回购是公司此前公告的最多4000万美元股份购回计划的落地执行。同时，知名机构LAV Asset Management于5月20日增持公司10.5万股，总金额约2373.92万港元，增持后持股比例升至13.00%。多重利好信号叠加，市场信心有所修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638790578","title":"映恩生物－Ｂ(09606)出現大手買入3.5萬股，成交價$214.0，涉資749萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2638790578","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638790578?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 11:15","pubTimestamp":1779851700,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在上午11:15出现大手买入，成交量为3.5万，成交价为港币$214.0，涉资749万。至目前为止，股价跌1.477%，今日最高价为$220.0，而最低价为$210.8，总成交量为22.8万股，总成交金额港币$4.913千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605275038/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605275038/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2543165471.USD","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171931366","title":"映恩生物-B回購3萬股股份，耗資約651.44萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171931366","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171931366?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 22:11","pubTimestamp":1779804697,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年5月26日公告，当日公司在香港联交所回购3万股普通股，占回购前已发行股本约0.0332%。该次回购价格介乎每股港币216.20元至218.40元，合计耗资约651.44万港元。回购股份将以库藏股形式持有。公司另披露，上述回购依据2025年6月20日通过的股份购回授权进行，授权可购回总数为8,803,626股。此次购回后授权余额为8,773,626股。于2026年5月26日收盘后，公司已发行股本增至90,524,414股，库藏股数为3万股，总股本为90,554,414股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B回购3万股股份，耗资约651.44万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638254814","title":"映恩生物-B(09606)5月26日斥資651.44萬港元回購3萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638254814","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638254814?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 22:04","pubTimestamp":1779804261,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，该公司于2026年5月26日斥资651.44万港元回购3万股股份，每股回购价格216.2-218.4港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252152.HKD","LU2543165471.USD","09606","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638851904","title":"LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股 每股作價226.0879港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638851904","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638851904?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 19:28","pubTimestamp":1779794912,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月20日，LAV Asset Management  Limited增持映恩生物-B10.5万股，每股作价226.0879港元，总金额约为2373.92万港元。增持后最新持股数目约为1175.79万股，最新持股比例为13.00%。本交易涉及其他关联方：施毅。补充资料：LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","EWH","LU2543165471.USD","09606","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636899445","title":"映恩生物-B早盤漲近5% 擬回購最多4000萬美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899445","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636899445?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 09:55","pubTimestamp":1779242100,"startTime":"0","endTime":"0","summary":"　　映恩生物-B盘中涨超6%，截至发稿，股价上涨4.83%，现报225.80港元，成交额9717.39万港元。　　5月19日，映恩生物-B发布公告，董事会拟行使公司股东于2025年6月 20日举行的股东周年大会上授予的一般授权项下的权力，于适当时机在公开市场购回公司股份。股份购回计划拟动用最多4000万美元购回股份。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-20/doc-inhypaet7044518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136251746","title":"異動解讀｜映恩生物-B盤中上漲5.66%，行使DB-1311美國市場選擇權後連續下挫迎來反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1136251746","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136251746?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 09:31","pubTimestamp":1779240703,"startTime":"0","endTime":"0","summary":"5月20日，映恩生物-B盘中上涨5.66%，报227.4港元，成交额794.67万港元。消息面上，公司此前于5月12日向BioNTech发出书面通知行使DB-1311/BNT324美国市场独家成本及利润/亏损分担选择权，股价自公告后连续多日下挫，从约257港元跌至5月19日的210.4港元，累计跌幅超18%。行使选择权后公司需向BioNTech支付其分担的过往开发成本，市场此前对公司短期资金压力的担忧有所缓解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636852631","title":"映恩生物-B(09606)擬回購最多4000萬美元股份 創始人朱忠遠擬增持不超過500萬美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636852631","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636852631?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 22:10","pubTimestamp":1779199828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 公布，董事会拟行使公司股东于2025年6月 20日举行的股东周年大会上授予的一般授权项下的权力，于适当时机在公开市场购回公司股份。董事会认为，股份当前成交价未能反映其内在价值及公司业务前景，现为公司购回股份的良机。董事会认为，股份购回计划符合公司及其股东的整体最佳利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226906","title":"映恩生物-B(09606)：通知行使DB-1311/BNT324成本及利潤╱虧損分擔選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226906?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 06:35","pubTimestamp":1778625346,"startTime":"0","endTime":"0","summary":"公司有权于首款 DB-1311/BNT324产品的首次2期临床试验成功完成后的特定期限内随时行使该选择权。此举使公司能够根据合作协议的条款分担首款DB-1311/BNT324产品于美国的开发成本以及商业化利润与亏损。董事会认为，DB-1311/BNT324于多种肿瘤适应症已展现出令人鼓舞的临床数据，该产品于美国具有巨大商业潜力，行使DB-1311/BNT324成本及利润╱亏损分担选择权使公司能够把握DB-1311于美国的潜力，行使该选择权符合公司及其股东的整体最佳利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4566","HK0000252160.HKD","HK0000252152.HKD","BK4585","BK4588","HK0000500386.USD","BK4118","DB","LU2543165471.USD","09606","BK4552","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1130590785","title":"映恩生物-B4月股份變動月報披露，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1130590785","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130590785?lang=zh_tw&edition=fundamental","pubTime":"2026-05-07 18:52","pubTimestamp":1778151130,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年5月7日公布4月股份变动月报，报告期为截至2026年4月30日。公司注册股本维持为200,000,000股普通股，面值每股0.0001美元，总注册股本为20,000美元，较上月无变动。报告期内，公司普通股由90,238,014股增至90,427,814股，主要因首次公开发售前股权激励计划的行使事项新增发行189,800股普通股。月末公司并无任何库藏股，整体股本总数较上月小幅增加。公司确认已遵守香港联交所《上市规则》及相关法律规定，所有股份发行均经董事会正式授权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105900092","title":"映恩生物-B（09606）2025年ADC佈局穩步拓展，收入18.52億元、淨虧損擴大至25.95億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105900092","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105900092?lang=zh_tw&edition=fundamental","pubTime":"2026-04-26 19:24","pubTimestamp":1777202687,"startTime":"0","endTime":"0","summary":"映恩生物-B聚焦抗体-药物偶联物研发，为癌症及自身免疫疾病提供创新疗法。根据报告内容，公司已在高度竞争且快速发展的ADC领域布局多款候选药物，并通过持续投入研发强化产品管线。财务数据显示，2025年度公司收入为18.52亿元人民币，较2024年的19.41亿元下降4.6%。从资产负债状况来看，截至2025年12月31日，资产总额为38.93亿元人民币，较2024年末的20.90亿元增长86.2%，负债总额则降至14.66亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物-B（09606）2025年ADC布局稳步拓展，收入18.52亿元、净亏损扩大至25.95亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629488548","title":"《大行》中金列出內地主動偏股型基金於港股首季重倉股情況(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629488548","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629488548?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 15:45","pubTimestamp":1776930300,"startTime":"0","endTime":"0","summary":"中金发表报告展示，内地公募基金于今年首季度的仓位变动：股票整体仓位略有下降，其中A股仓位上升，港股仓位下降较多。主动偏股型基金方面，资产总值较上季度小幅回落至不足3万亿人民币；股票资产规模略降至2.6万亿人民币，仓位下降0.9个百分点至86.1%；A股仓位由上季度的72.3%继续上升至73.9%，但仍处于近10年较低水平。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180509171357285_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180509171357285_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1519827/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1519827/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01801","01787","03690","HPAD.SI","02601","01818","02628","00939","06869","00857","00700","00175","CNHmain","UCmain","06160","02423","00941","002594","00981","09926","HTCD.SI","LNNGY","09606","01318","09858","GELYY","MUCmain","01378","09988","01347","01093","601318","MCNHmain","BABA","06990","00883","01109","HYDD.SI","01138","BYDDY","02899","02318","01519","HMTD.SI","02331","01211","02319","01070","09992","01530"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":168,"code":"91000000","status":"200"}]}}